Compare Fox Corp Class A (FOXA) vs Sana Biotechnology Inc (SANA) Price & Performance

FOXA trades at $62.30, down 1.77% on the day, with a bullish technical signal and strong quarterly earnings beats. Recent Q2 2026 EPS of $1.79 exceeded the $1.44 estimate, driven by World Cup advertising and Tubi streaming growth. The stock shows robust fundamentals with a P/E of 16.18 and net income margin of 9.84%, supported by $3.32B in operating cash flow for 2025.

The outlook is positive with a $65.33 consensus price target and 50% analyst buy ratings, though risks include reliance on sports rights and projected 2026 net cash flow decline. Upside hinges on sustained ad demand and digital segment execution amid competitive pressures.

SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.

The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.